The role of intratumoral lymphovascular density in distinguishing primary from secondary mucinous ovarian tumors

Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.

Download Full-text

The role of estrogen in the survival of ovarian tumors—A study of the human ovarian adenocarcinoma cell lines OC-117-VGH and OVCAR3

Journal of the Chinese Medical Association ◽

10.1016/j.jcma.2012.08.023 ◽

2013 ◽

Vol 76 (2) ◽

pp. 63-70 ◽

Cited By ~ 3

Author(s):

Kuan-Chong Chao ◽

Peng-Hui Wang ◽

Chi-Ching Chang ◽

Ming-Shyen Yen ◽

Chin-Wen Chi

Keyword(s):

Cell Lines ◽

Ovarian Tumors ◽

Ovarian Adenocarcinoma ◽

Adenocarcinoma Cell

Download Full-text

MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: Possible implications for the role of desmoplastic fibroblasts

Human Pathology ◽

10.1016/s0046-8177(98)90226-x ◽

1998 ◽

Vol 29 (2) ◽

pp. 155-165 ◽

Cited By ~ 52

Author(s):

Saliha Afzal ◽

El-Nasir Lalani ◽

Richard Poulsom ◽

Andrew Stubbs ◽

Gail Rowlinson ◽

...

Keyword(s):

Mrna Expression ◽

Ovarian Tumors

Download Full-text

Evaluation of immunohistochemical expression of mismatch repair proteins in endometrioid and seromucinous borderline ovarian tumors a 10-year experience in a large health care institution.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e17557 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e17557-e17557

Author(s):

Hector Chavarria ◽

Marina Frimer ◽

Noah D. Kauff ◽

Veena S. John ◽

Seema Khutti

Keyword(s):

Mismatch Repair ◽

Ovarian Tumors ◽

Borderline Tumor ◽

Nuclear Staining ◽

Immunohistochemical Expression ◽

Stromal Invasion ◽

Borderline Tumors ◽

Dna Mismatch ◽

Mismatch Repair Proteins

e17557 Background: Borderline tumors (BT) are atypical proliferation of epithelium in the ovary in the absence of destructive stromal invasion, representing for 15% of all epithelial ovarian cancers. [1] Around 10% of the ovarian tumors are hereditary, and approximately 10% of all the hereditary forms of epithelial ovarian tumors are result of a loss of DNA mismatch repair (MMR). [2] Endometrioid borderline tumor (EBT) and Seromucinous borderline tumors (SMBT) are rare tumors in ovary and there is limited literature available on immunohistochemical (IHC) expression of Mismatch repair proteins(MMRP)in these tumors.[3, 4] The aim of this study is to evaluate IHC expression of MMRP in EBT and SMBT of ovary. Methods: Pathology database was searched for ovarian Endometrioid borderline tumor (EBT) and Seromucinous borderline tumor (SMBT) for a 10-year period (2010-2020). The cohort consisted of 10 EBT (6 of which had focal microinvasion or carcinoma) and 12 SMBT(2 of which had focal carcinoma ). For comparison, 1 borderline Brenner. 15 serous borderline tumors (SBT) and 15 mucinous borderline tumors (MBT) were also included. After reviewing slides, a block with adequate borderline tumor was selected for IHC stains. For the cases with carcinoma, two different blocks with each component were selected. In all selected blocks, IHC stains for four MMRP (MLH1, PMS2, MSH2, MSH6) were performed. The complete absence of nuclear staining in tumor cells was considered as “loss” of the MMRP expression. Any “weak” or “focal” nuclear staining was considered intact. Results: Total 53 cases were evaluated for MMRP IHC. All cases had intact MMRP expression. In cases with carcinoma, both components (BT and carcinoma) have intact MMR IHC expression. See table. Conclusions: Our study did not show loss of MMRP IHC expression in EMT or SMBT. However, our study consisted of a small number of cases. Multi Institutional study with a large number of cases can be helpful in future to further evaluate the role of MMRP IHC in EMT and SMBT. [Table: see text]

Download Full-text